Navigation Links
Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow is Another One's Joy

LONDON, January 18, 2013 /PRNewswire/ --

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost patent protection. StockCall has technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is available for free upon registration at    

The generic drug industry has been feasting on patent expirations in recent years, and if the start of 2013 is anything to go on, this year could see more of the same. Major branded drug companies have lost exclusivity rights to a number of top selling products, and generic alternatives, as well as customer's pockets, have been the main beneficiaries.

Mylan only recently announced that it is now releasing its generic of Pfizer's Dilantin tablets after receiving the FDA's seal of approval. Dilantin is given for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery. According to IMS Health, the 50 mg chewable tablet saw U.S. sales of close to $16.5 million for a 12 month period ending September 30, 2012. See our technical analysis on Mylan by sign up now at

Also in news lately has been Watson Pharmaceuticals Inc.'s [Free Analysis Report on WPI] [(1)] generic version of Ferring Pharmaceuticals' Lysteda tablet which received the FDA's approval even as an infringement lawsuit against Watson Pharma has been filed by the original maker of the drug. Whilst this legal battle is still pending, Watson Pharma intends to make the most of the time to launch its generic version. Last year, Lysteda saw revenues of close to $25 million in the U.S.

Generic companies also currently have an impressive list of abbreviated new drug applications awaiting FDA approval. Those that have first-to-file status have the potential to be even more lucrative as these companies can enjoy a period of generic exclusivity that is usually 180 days.  

Select generic drug makers have been focusing on expansion of late, in an attempt to grow sales and profits. Some have been acquiring competitors, while others have been investing in growing their presence abroad. Regardless, generic drug companies appear to be in a strong position to grow in 2013.


  1. Watson Pharmaceuticals Inc. Technical Analysis [ ]

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
2. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
3. Notre Dame to be part of $194 million university research center network
4. Researchers create method for more sensitive electrochemical sensors
5. Global Soil Treatment Market Forecast to Grow at a CAGR of 8.5% to 2017 in New Research Report at
6. Global Healthcare Contract Research Outsourcing Market is expected to reach USD 65.03 billion by 2018: Transparency Market Research
7. Nanofiber Production Device Set to Accelerate Research into Nanofiber Applications in Medicine
8. CIS MDI (Methyl Diphenyl Diisocyanate) Market - New Industry Research Report Published by Transparency Market Research
9. Butanes Market - New Industry Research Report Published by Transparency Market Research
10. New research gives insight into graphene grain boundaries
11. Sustainable Valley Technology Group Provides Technology Innovation Grant To Help Researchers & Start-Ups With Funding, Business Support, Equipment & Facilities
Post Your Comments:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
Breaking Biology News(10 mins):